Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Final Analysis of Pregnancy Outcomes Following Exposure to Dimethyl Fumarate in a Prospective International Registry
Multiple Sclerosis
S31 - MS Clinical Decision Making and Special Populations (4:06 PM-4:18 PM)
004
Oral delayed-release DMF has a favorable benefit-risk profile in treating people with multiple sclerosis (PwMS) and should be used in pregnant women only if the potential benefits outweigh the potential risk to the fetus. 
To assess pregnancy outcomes and DMF exposure in a completed international registry (NCT01911767, TecGistry) of women with MS exposed to dimethyl fumarate (DMF). 
TecGistry includes women with MS exposed to DMF from the first day of their last menstrual period before conception or during pregnancy, with data collected at enrollment, 6-7 months gestation, 4 weeks after estimated due date, and at 4, 12, and 52 weeks postpartum.  Outcomes collected included live births, pregnancy loss, ectopic/molar pregnancies, birth defects and anomalies, and infant or maternal death after delivery.  Gestational weight was classified by percentile (<10th, 10th−90th, >90th), which was based on standardized growth charts.
As of 13 May 2022, 397 women with MS were enrolled, with a median age of 32 years (range: 19, 43). Median gestation week at first DMF exposure was 1 (range: 0, 13) and at enrollment was 10 (range: 0, 39). Median duration of gestational DMF exposure was 5 weeks (range: 0, 40). Among DMF discontinuations, one was due to serious AE. Fifteen (3.8%) spontaneous abortions occurred. Of the 360 live births, 323 (90%) were full term and 37 (10%) were premature (<37 weeks). Gestational weight data was available for 282 infants, in which 32 (11.3%) were classified as small, 240 (85.1%) as appropriate, and 10 (3.5%) as large. One neonatal death and no maternal deaths occurred. Overall, 13 (3.6%) infants had adjudicator-confirmed MACDP birth defects and 8 (2.2%) had adjudicator-confirmed EUROCAT birth defects.
Dimethyl fumarate exposure during pregnancy did not adversely affect pregnancy outcomes, with no increased incidence of birth defects and no increased rate of spontaneous abortion.
Authors/Disclosures
Kerstin Hellwig (St. Josef Hospital Bochum)
PRESENTER
Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for INC research . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer . The institution of Kerstin Hellwig has received research support from Roche . The institution of Kerstin Hellwig has received research support from Merck . The institution of Kerstin Hellwig has received research support from Biogen. The institution of Kerstin Hellwig has received research support from Genzyme . The institution of Kerstin Hellwig has received research support from Novartis . The institution of Kerstin Hellwig has received research support from TEVA.
David Rog, MBBS Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Dr. Rog has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MedDay. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen-Cilag. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. The institution of Dr. Rog has received research support from Actelion. The institution of Dr. Rog has received research support from Biogen. The institution of Dr. Rog has received research support from MedDay. The institution of Dr. Rog has received research support from Merck. The institution of Dr. Rog has received research support from Mitsubishi. The institution of Dr. Rog has received research support from Novartis. The institution of an immediate family member of Dr. Rog has received research support from Sanofi Genzyme. The institution of Dr. Rog has received research support from TG Therapeutics. Dr. Rog has received research support from Janssen-Cilag.
Christopher McGuigan, MD Dr. McGuigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. McGuigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. McGuigan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Dr. McGuigan has received research support from Biogen. The institution of Dr. McGuigan has received research support from Novartis. The institution of Dr. McGuigan has received research support from Roche.
Maria K. Houtchens, MD Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche . Dr. Houtchens has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Serono. Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Cravath. Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Beasley . Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Biogen. The institution of Dr. Houtchens has received research support from Genzyme. The institution of Dr. Houtchens has received research support from Biogen. The institution of Dr. Houtchens has received research support from Genentech.
Denise *Use 379955 Bruen Denise Bruen has received personal compensation for serving as an employee of Can Do MS. Denise Bruen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Denise Bruen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Denise Bruen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme. Denise Bruen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Denise Bruen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics.
Oksana Mokliatchouk Oksana Mokliatchouk has received personal compensation for serving as an employee of Biogen. Oksana Mokliatchouk has received stock or an ownership interest from Biogen.
Filipe Branco Filipe Branco has received personal compensation for serving as an employee of Biogen. Filipe Branco has received stock or an ownership interest from Biogen.
Seth Nathatn Levin, MD (Biogen) Dr. Levin has received personal compensation for serving as an employee of Biogen. Dr. Levin has received stock or an ownership interest from Biogen.
Xiaochen Lin, PhD (Biogen) Dr. Lin has received personal compensation for serving as an employee of Biogen. Dr. Lin has stock in Biogen.